ERIS Lifesciences Ltd is engaged in the business of manufacture and marketing of pharmaceutical products.
Financial Results:
ERIS Lifesciences Ltd reported Revenues for Q3FY24 of ₹486.00 Crores up from ₹423.00 Crore year on year, a rise of 14.89%.
Total Expenses for Q3FY24 of ₹375.00 Crores up from ₹319.00 Crores year on year, a rise of 17.55%.
Consolidated Net Profit of ₹101.00 Crores up 1.0% from ₹100.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹7.55, up 0.80% from ₹7.49 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.